Print

Purpose

Reduced drug use is a clinically meaningful target for treatment development, but few studies have evaluated the positive impacts produced by this behavioral change, preventing adoption of this endpoint in clinical trials. The proposed research will fill that critical knowledge gap by demonstrating the biopsychosocial benefits of reduced methamphetamine use. These data will be used to change current accepted methamphetamine treatment endpoints and accelerate identification of therapies for methamphetamine use disorder.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • be age 18 years or older; - self-report methamphetamine use in the week prior to screening; - provide a methamphetamine-positive urine sample at screening; - meet DSM-5 criteria for moderate-severe Methamphetamine Use Disorder (MUD); - be seeking treatment for their methamphetamine use - be able and willing to commit to the 12-week intervention, as well as the 12-week post-intervention follow-up - Individuals who meet these criteria and are stably maintained on buprenorphine or methadone for Opioid Use Disorder (OUD) will also be eligible to participate.

Exclusion Criteria

  • current or past medical or psychiatric illness (e.g., physical dependence on any drug other than buprenorphine requiring medically managed detoxification, unstable angina, uncontrolled cardiac arrhythmia, aortic stenosis, self-reported compromised immune function, severe diagnosis for a SUD other than MUD or treated OUD) that would interfere with study participation in the opinion of the study physicians - poor venous access precluding blood draws

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Basic Science
Masking
Double (Care Provider, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
No Intervention
Control Group 		This group will receive payment for providing urine samples throughout the trial.
Experimental
Contingency Management Group 		This group will receive payment for providing methamphetamine negative urine samples throughout the trial.
  • Behavioral: Contingency Management
    Subjects will receive payments for providing methamphetamine negative urine samples.

Recruiting Locations

UK Center for Clinical and Translational Science and nearby locations

Psychopharmacology of Addiction Laboratory
Lexington, Kentucky 40507
Contact:
William W Stoops, PhD
859-257-5388
william.stoops@uky.edu

More Details

NCT ID
NCT07226596
Status
Recruiting
Sponsor
William Stoops

Study Contact

William W Stoops, PhD
8592575388
william.stoops@uky.edu

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.